Der findes ingen kontrollerede epidemiologiske data vedrørende risikoen med Angiotensin II- Receptor - Antagonister (AIIRAer), men lignende risici kan findes for denne lægemiddelgruppe.
Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs.